Deleted in liver cancer-1 (DLC1): an emerging metastasis suppressor gene
Nicholas C Popescu1, Steve Goodison
1Laboratory of Experimental Carcinogenesis, National Cancer Institute, Building 37, Room 4140, 37 Convent Dr., MSC 4262, Bethesda, MD, 20892-4262, USA, popescun@dc37a.nci.nih.gov.
Abstract:
While significant progress continues to be made in the early detection and therapeutic management of primary tumors, the incidence of metastatic disease remains the major cause of mortality. Accordingly, the development of novel effective therapies that can ameliorate dissemination and secondary tumor growth are a clinical priority. The identification of genetic and functional alterations in cancer cells that affect factors implicated in the metastatic process is critical for designing preventive and therapeutic strategies. Evidence implicating the protein deleted in liver cancer-1 (DLC1), a Rho GTPase activator, in metastasis has accumulated to a point where DLC1 may be considered as a metastasis suppressor gene. This review presents evidence supporting an anti-metastatic role for DLC1 in several human cancers and discusses the mechanisms contributing to its inhibitory effects. In addition, promising opportunities for therapeutic interventions based on DLC1 function and downstream pathways involved in the metastatic process are considered.
Insights
The protein deleted in liver cancer-1 (DLC1) acts as a metastasis suppressor, inhibiting cancer spread and secondary tumor growth. Understanding DLC1's function offers new therapeutic strategies for reducing cancer mortality.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metastasis Research
Background:
- Metastatic disease is the primary cause of cancer-related mortality, underscoring the need for novel anti-metastatic therapies.
- Identifying genetic factors influencing cancer cell dissemination is crucial for developing effective treatment and prevention strategies.
Purpose of the Study:
- To review the evidence supporting the role of deleted in liver cancer-1 (DLC1) as a metastasis suppressor gene.
- To discuss the mechanisms by which DLC1 inhibits cancer metastasis.
- To explore therapeutic opportunities targeting DLC1 and its downstream pathways.
Main Methods:
- Literature review of studies investigating DLC1's role in cancer metastasis.
- Analysis of genetic and functional alterations affecting DLC1.
- Examination of DLC1's downstream signaling pathways involved in metastasis.
Main Results:
- Accumulating evidence implicates DLC1 as a suppressor of metastasis in various human cancers.
- DLC1, a Rho GTPase activator, exerts inhibitory effects on cancer cell dissemination and secondary tumor formation.
- DLC1's function is linked to key pathways regulating the metastatic process.
Conclusions:
- DLC1 is a critical suppressor of cancer metastasis with significant therapeutic potential.
- Targeting DLC1 and its associated pathways presents a promising strategy for novel anti-cancer therapies.
- Further research into DLC1 function can lead to improved treatments for metastatic disease.
Related Concept Videos
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:12Loss of Tumor Suppressor Gene Functions
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
02:39lncRNA - Long Non-coding RNAs
02:23Abnormal Proliferation